Drugs and Devices

FDA approves expanded use of Isentress in children and adolescents

The U.S. Food and Drug Administration has approved Isentress (raltegravir) for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2 to 18. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares